Download presentation
Presentation is loading. Please wait.
Published byEugenia Shavonne Merritt Modified over 6 years ago
1
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic Oncology Volume 12, Issue 7, Pages e96-e97 (July 2017) DOI: /j.jtho Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions
2
Figure 1 (A) Chest computed tomography images at baseline before nivolumab treatment (left) and after 5 months of nivolumab therapy (right) in a patient with NSCLC with underlying pulmonary fibrosis that reveal a decrease in size of the dominant left hilar mass. (B) Pulmonary function tests before and after treatment with nivolumab. FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; Dlco, diffusion capacity of lung for carbon monoxide. Journal of Thoracic Oncology , e96-e97DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.